For women. I am not pregnant. I agree to tell my provider if I become pregnant or think I may be pregnant. The safety of buprenorphine in pregnancy is unknown, and if I become pregnant, I will discuss treatment options with my buprenorphine provider.
For women. If you use opioid medications while pregnant, the baby can be born addicted to opioids. I will tell my doctor right away if I am or I become pregnant.
For women. This is of course important but interestingly these objectives seem to focus only on women but do not mention fathers as a target group. It is highly advisable to include fathers explicitly into these objectives and measures. The feedback from the IFIN- HH implementation team on this report points out that these measures are addressing - in accordance with Rumanian legislation - all employees and can therefore be used by men and women. Nevertheless, from the standpoint of the evaluation it is considered important that men are explicitly targeted and motivated to make use of family friendly policies to get more involved into childcare activities. In the GEP gender inequalities are described as originating from cultural, social and biological origins. Women and men are rather seen as “complementary than as identical” (GEP IFIN HH, p.4) which can cause gender inequalities. This is a problematic statement as it leaves open in which way they are complementary and constructs women and men as two distinct but homogenous groups. This suggests that women are more suited for specific tasks like childrearing, caring than men which are more able to perform different sets of tasks and responsibilities. This will not contribute to reducing gender equality but will freeze existing gender inequalities. Furthermore, gender inequalities stemming from biological differences cannot be tackled through a GEP. Therefore it seems inappropriate to refer to biological origins in a GEP. It is not really clear from the GEP who will responsible for its implementation (GEP). Therefore it is advisable to appoint someone with sufficient resources and expertise for implementing the GEP measures. Process of (GEP) design – descriptive The GEP was designed by the IFIN-HH GENERA team. Other stakeholders within the organisation were not involved in designing the GEP due to a lack of interest and awareness (IP2+3). The guidelines and minimum standards for developing a GEP agreed upon by all GENERA implementation managers in Munich in May 2017 were taken into account (GEP, p.5). Process of implementation – descriptive As the GEP was not approved at the time of the interviews the implementation of suggested measures has not started. Besides the GIPD and the data collection on the status quo of gender equality in careers in physics no other measures have been implemented in the course of the GENERA project. Most challenging At IFIN-HH male and female researchers are nearly equally represented as 4...
For women. I will avoid getting pregnant while taking these medications. To the best of my knowledge, I am not pregnant at this time. I understand pregnancy tests may be completed by PCWFL. SECURITY My initials indicate I have carefully read, fully understand, and agree to this section of the agreement.
For women. Have you been pregnant? If yes, how many times?
For women. If your score on “
For women. If I am pregnant or intend to become pregnant, I am required to notify Ivy Collaborative Healthcare immediately to discuss tapering off medication(s) that could potentially harm the baby. I understand that my failure to do so may result in discharge from the practice. I will not hold Ivy Collaborative Healthcare responsible for any harm that may occur to my and/or my unborn. My signature below indicates that I have read this document and understand it. I have had all of my questions answered to my satisfaction. I agree to honor this policy above and I understand that failure to abide by this agreement will result in my termination of controlled medication prescriptions and possibly termination of services from Ivy Collaborative Healthcare. Patient/Guardian Signature: Date:
For women. You agree that additional risks may be associated with the use of controlled substances during pregnancy. This includes, but is not limited to birth defects, problems with development and behavior, and neonatal abstinence syndrome. If you are intending to become pregnant, or find that you are pregnant, you will notify the prescriber immediately to discuss potential treatment changes. You understand and agree that failure to adhere to these policies will be considered a breach of this agreement and may result in discontinuation of medication prescribing by this clinic and possible dismissal from this clinic. You affirm that you have full right and power to sign and be bound by this agreement. You further affirm that you have been given the opportunity to ask any questions you may have and that you have read, understand, and accept all of its terms. Patient Signature: Date: Patient Name (Print): Prescriber: Date:
